SATELLITE SYMPOSIUM SUPPORTED BY BIOENVISION,
CEPHALON ONCOLOGY, ROCHE AND SUPERGEN
08.00 – 10.00 hours, Room: Auditorium
THE M.D. ANDERSON CANCER CENTER APPROACH TO
PATIENTS WITH HEMATOLOGIC MALIGNANCIES
Chair: M.J. Keating (The University of Texas M.D. Anderson Cancer
Center, Houston, USA)
08.00 – 08.20 hours
NEW TYROSINE KINASE INHIBITORS IN CHRONIC
MYELOID LEUKEMIA
S. O’Brien (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
08.20 – 08.40 hours
OPTIMIZING TREATMENT OF CHRONIC LYMPHOCYTIC
LEUKEMIA
M.J. Keating (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
08.40 – 09.00 hours
USING CELLULAR PHARMACOLOGY IN THE EVALUATION
OF NEW AGENTS
V. Gandhi (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
09.00 – 09.20 hours
RECENT STUDIES IN ADULT AND PEDIATRIC ACUTE
LEUKEMIA
H.M. Kantarjian (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
09.20 – 09.40 hours
NOVEL TREATMENT STRATEGIES FOR REFRACTORY
NON-HODGKIN’S LYMPHOMA
L. Fayad (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
09.40 – 10.00 hours
IMPROVING THE PREVENTION AND CONTROL
OF GRAFT-VS-HOST DISEASE
R. Champlin (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
SATELLITE SYMPOSIUM SUPPORTED BY SHIRE
08.00 – 10.00 hours, Room: Forum
THE FUTURE OF ESSENTIAL THROMBOCYTHAEMIA UNFOLDS:
IMPLICATIONS FOR DIAGNOSIS AND MANAGEMENT
Chairs: S. Zweegman (VU University Medical Center, Amsterdam,
The Netherlands)
G. Birgegård (University Hospital, Uppsala, Sweden)
BUFFET BREAKFAST AVAILABLE FROM 08.00 HOURS
08.30 – 08.35 hours
INTRODUCTION AND WELCOME
S. Zweegman (VU University Medical Center, Amsterdam,
The Netherlands)
08.35 – 08.55 hours
JAK2 EXAMINED: RE-THINKING CLASSIFICATION
AND DIAGNOSIS?
J. Reilly (Royal Hallamshire Hospital, Sheffield, United Kingdom)
08.55 – 09.15 hours
MEGAKARYOCYTES EXPOSED: WHAT CAN THEY TELL US?
J. Thiele (University of Cologne, Cologne, Germany)
09.15 – 09.35 hours
MANAGING ESSENTIAL THROMBOCYTHAEMIA:
WHERE ARE WE TODAY?
C. Besses (Hospital del Mar, Barcelona, Spain)
09.35 – 09.50 hours
FUTURE MANAGEMENT: WHAT WILL WE BE DOING IN
2010?
G. Birgegård (University Hospital, Uppsala, Sweden)
09.50 – 10.00 hours
QUESTIONS AND CLOSING REMARKS
S. Zweegman (VU University Medical Center, Amsterdam,
The Netherlands)
SATELLITE SYMPOSIUM SUPPORTED BY ALEXION PHARMACEUTICALS
08.00 – 10.00 hours, Room: X
CRITICAL CHALLENGES AND EMERGING THERAPIES FOR PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA (PNH) - A YEAR 2006 UPDATE
07.30 – 08.00 hours
CONTINENTAL BREAKFAST
08.00 – 08.15 hours
OVERVIEW AND INTRODUCTION
P. Hillmen (Leeds Teaching Hospitals NHS Trust, Leeds,
United Kingdom)
08.15 – 08.35 hours
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA HISTORY,
EPIDEMIOLOGY, AND BIOLOGY
L. Luzzatto (University of Genova, Genova, Italy)
08.35 – 08.55 hours
RELATIONSHIP BETWEEN PNH AND OTHER
HEMATOLOGICAL DISORDERS: BIOLOGICAL BASIS OF APLASTIC ANEMIA AND RELATED
HEMATOLOGICAL DISORDERS
A. Tichelli (University Hospital Basel, Basel, Switzerland)
08.55 – 09.15 hours
THROMBOSIS SYNDROMES IN PNH - CRITICAL
CHALLENGES IN ASSESSMENT AND MANAGEMENT OF SEVERE AND LIFE THREATENING
THROMBOTIC COMPLICATIONS OF PNH
A. Hill (Leeds General Infirmary, Department of Haematology, Leeds,
United Kingdom)
09.15 – 09.45 hours
COMPLEMENT INHIBITION AND OTHER THERAPEUTIC
APPROACHES FOR MANAGEMENT OF PNH - WHEN, WHY, HOW, AND UNDER WHAT
CONDITIONS SHOULD SPECIFIC THERAPIES BE EMPLOYED
P. Hillmen (Leeds Teaching Hospitals NHS Trust, Leeds,
United Kingdom)
09.45 – 10.00 hours
QUESTIONS & ANSWERS: INTERACTIVE SESSION
Support for this activity has been made possible by educational grants
from Celgene Corporation and Cephalon, Inc and OrthoBiotech
SATELLITE SYMPOSIUM SUPPORTED BY
MULTIPLE MYELOMA RESEARCH FOUNDATION
07.30 – 10.00 hours, Room: Y
INTEGRATION OF NOVEL THERAPIES INTO CURRENT
TREATMENT OF MYELOMA: AN EVOLVING PARADIGM
Course Director: H. Klingemann (Tufts University School of Medicine,
Boston, Massachusetts, USA)
APPROACHES TO INITIAL THERAPY
M.A. Dimopoulos (The University of Athens School of Medicine,
Kifissia, Athens, Greece)
APPROACHES TO BONE MARROW TRANSPLANTATION
J. L. Harousseau (University Hospital Nantes, Nantes, France)
MANAGEMENT OF RELAPSED AND REFRACTORY DISEASE
P. Richardson (Harvard Medical School, Dana-Farber Cancer Institute,
Boston, Massachusetts, USA)
GENOMICS AND CLINICAL DECISION MAKING: STATE OF
THE ART
J. Drach (Medical University Vienna, Vienna, Austria)
NOVEL TARGETS, NOVEL AGENTS
K. Anderson (Harvard Medical School, Dana-Farber Cancer Institute,
Boston, Massachusetts, USA
SATELLITE SYMPOSIUM SUPPORTED BY NEBO A/S
08.00 – 10.00 hours, Room: A
IV IRON IN HAEMATOLOGY – AN ALTERNATIVE TO
BLOOD TRANSFUSIONS?
Chair: M. Auerbach (Georgetown University School of Medicine, Currently
in Private Practice, Baltimore, USA)
08.00 – 08.05 hours
WELCOME AND INTRODUCTION
M. Auerbach (Georgetown University School of Medicine, Currently in
Private Practice, Baltimore, USA)
08.05 – 08.25 hours
HOW TO DECIDE ON IRON OR BLOOD,
WHEN ANAEMIA IS DIAGNOSED?
A. Lakhani (Bromley Hospitals NHS Trust, Orpington Kent,
United Kingdom)
08.25 – 08.55 hours
IRON TOXICITY – NOT ALL IV IRON FORMULATIONS ARE
ALIKE
R. Agarwal (Indiana University School of Medicine, Indianapolis, USA)
08.55 – 09.15 hours
CLINICAL EXPERIENCE WITH TOTAL DOSE IV IRON
INFUSION (TDI)
M. Auerbach (Georgetown University School of Medicine, Currently in
Private Practice, Baltimore, USA)
09.15 – 09.45 hours
REDUCTION IN BLOOD TRANSFUSIONS - A BENEFIT FOR
PATIENTS AND HAEMATOLOGY WARDS
P. Stross (Department of Haematology, St Richard's Hospital,
Chichester, United Kingdom)
09.45 – 10.00 hours
QUESTIONS AND CLOSING REMARKS
SATELLITE SYMPOSIUM SUPPORTED BY THE MYELODYSPLASTIC SYNDROMES (MDS)
FOUNDATION
08.00 – 10.00 hours, Room: B
AN EVOLUTION IN THE UNDERSTANDING OF MYELODYSPLASTIC SYNDROMES
Chairs: G.J. Mufti (King’s College Hospital, London, United Kingdom)
P. Fenaux (Hôpital Avicenne, Bobigny, France)
PROBLEMS IN THE MORPHOLOGICAL DIAGNOSIS OF MDS
B. Bain (St. Mary’s Hospital, London, United Kingdom)
CORRELATION AND DIFFERENTIATION OF NEW
THERAPEUTIC AGENTS THROUGH UNIFORM RESPONSE CRITERIA IN MDS
J. Bennett (University of Rochester, James P. Wilmot Cancer Center,
Rochester, USA)
THE RELATIONSHIP OF QUALITY-OF-LIFE TO HGB
LEVELS IN MDS
E. Hellström-Lindberg (Karolinska Institutet, Huddinge University
Hospital, Stockholm, Sweden)
THE INTER-RELATIONSHIP OF INEFFECTIVE
HEMATOPOIESIS AND CELLULAR BIOLOGY IN MDS
G. Kroemer (Institut Gustave Roussy, Villejuif, France)
CLARIFYING MDS - A PROGRESS REPORT ON RESEARCH
IN MOLECULAR BIOLOGY
C. Schoch (Laboratory for Leukemia Diagnostics, University
Hospital Grosshaderen, Munich, Germany)
SATELLITE SYMPOSIUM SUPPORTED BY APOPHARMA
08.00 – 10.00 hours, Room: L
LIFE IS GETTING LONGER - AN UPDATE ON SURVIVAL DATA
08.00 – 08.05 hours
WELCOME / SESSION OVERVIEW
V. Hoffbrand (Royal Free and University College School of Medicine,
London, United Kingdom)
08.05 – 08.20 hours
HISTORICAL PERSPECTIVE OF SURVIVAL IN
THALASSAEMIA
V. Hoffbrand (Royal Free and University College School of Medicine,
London, United Kingdom)
08.20 – 08.40 hours
ARE CURRENT MEASUREMENTS ACCURATE PREDICTORS OF
MORBIDITY/MORTALITY?
A. Piga (University of Torino, Torino, Italy)
08.40 – 09.00 hours
HOW CAN MRI BE USED TO OPTIMIZE THERAPY?
D. Pennell (Royal Brompton Hospital, London, United Kingdom)
09.00 – 09.30 hours
IS THERE A LINK BETWEEN RATES OF SURVIVAL
AND CHOICE OF IRON CHELATOR?
P. Telfer (St.Bartholomew’s and The Royal London NHS Trust, London,
United Kingdom)
09.30 – 09.55 hours
QUESTIONS & ANSWERS
Faculty
09.55 – 10.00 hours
SUMMARY & CLOSING
V. Hoffbrand (Royal Free and University College School of Medicine,
London, United Kingdom)
SATELLITE SYMPOSIUM SUPPORTED BY CEPHALON
08.00 – 10.00 hours, Room: C
UNMET NEEDS AND NEW TREATMENT TRENDS IN AML
Chair: B. Löwenberg (Erasmus Medical Center, Rotterdam,
The Netherlands)
TRENDS IN THE TREATMENT OF AML
B. Löwenberg (Erasmus Medical Center, Rotterdam, The Netherlands)
OPTIONS FOR THE OLDER PATIENT WITH AML
A. Burnett (University of Wales, Cardiff, Wales)
EVOLVING CONCEPTS IN THE FRONT LINE TREATMENT
OF APL
F. Lo Coco (Tor Vergata University, Rome, Italy)
THE PROMISE OF FLT3 INHIBITORS IN AML
M. Levis (Johns Hopkins University, Baltimore, USA)
PANEL DISCUSSION AND CLOSE
SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS
10.45 – 12.45 hours, Room: Main Auditorium
BACK IN BALANCE: MANAGING IRON OVERLOAD TO IMPROVE PATIENT OUTCOMES
10.45 – 10.50 hours
INTRODUCTION
J.B. Porter (University College, London, United Kingdom)
10.50 – 11.20 hours
GOALS OF IRON CHELATION THERAPY: WHAT ARE WE
LEARNING FROM THE LATEST IRON SCIENCE?
J.B. Porter (University College, London, United Kingdom)
11.20 – 11.40 hours
CHELATION IN THE CONTEXT OF THE LATEST IRON
SCIENCE
A. Kattamis (University of Athens School of Medicine, Athens, Greece)
11.40 – 11.50 hours
QUESTIONS & ANSWERS
11.50 – 12.10 hours
NEW TRENDS IN CHELATION: IMPACTING OUTCOMES
A.T. Taher (American University of Beirut Medical Center,
Beirut, Lebanon)
12.10 – 12.30 hours
NEW TRENDS IN CHELATION: CONVENIENCE IS
EXPECTED TO INCREASE USE OF TREATMENT
N. Gatterman (Heinrich-Heine-University, Düsseldorf, Germany)
12.30 – 12.40 hours
QUESTIONS & ANSWERS
12.40 – 12.45 hours
SUMMARY, CONCLUSIONS, AND CLOSE
J.B. Porter (University College, London, United Kingdom)
12.45 – 13.30 hours
LUNCH
SATELLITE SYMPOSIUM SUPPORTED BY SCHERING AG
10.45 – 12.45 hours, Room: Forum
PRACTICAL APPROACHES TO TREATING TODAY'S
HAEMATOLOGICAL MALIGNANCIES
Chair: E. Kimby (Karolinska University Hospital, Stockholm, Sweden)
10.45 – 11.15 hours
BISPHOSPHONATE THERAPY IN MULTIPLE MYELOMA
E. McCloskey (Northern General Hospital, Sheffield, United Kingdom)
11.15 – 11.45 hours
A NEW STANDARD FOR FIRST-LINE THERAPY IN
CHRONIC LYMPHOCYTIC LEUKAEMIA
P. Hillmen (Leeds Teaching Hospitals NHS Trust, Leeds,
United Kingdom)
11.45 – 12.15 hours
OPTIMIZING TREATMENT FOR CHRONIC LYMPHOCYTIC
LEUKAEMIA WITH MABCAMPATH
C. Dearden (Royal Marsden Hospital, Sutton, United Kingdom)
12.15 – 12.45 hours
RADIOIMMUNOTHERAPY WITH ZEVALIN: A PROMISING
NEW THERAPY FOR RITUXIMAB-RELAPSED FOLLICULAR LYMPHOMA
F. d'Amore (Aarhus University Hospital, Aarhus C, Denmark)
SATELLITE SYMPOSIUM SUPPORTED BY PHARMION CORPORATION LTD
10.45 – 12.45 hours, Room: X
CASE-BASED APPROACHES TO THE MANAGEMENT
OF MULTIPLE MYELOMA
Chair: K.C. Anderson (Harvard Medical School–Dana-Farber Cancer
Institute, Boston, USA)
10.15–10.45 hours
BREAKFAST BUFFET
10.45–12.45 hours
NEW TREATMENT PARADIGMS IN MYELOMA
K.C. Anderson (Harvard Medical School–Dana-Farber Cancer Institute,
Boston, USA)
CASE PRESENTATION: COMBINATION THERAPY
IN THE RELAPSED/REFRACTORY PATIENT
R. García-Sanz (University of Salamanca, Salamanca, Spain)
CASE PRESENTATION: THE NEWLY DIAGNOSED PATIENT
J.F. San Miguel (University of Salamanca, Salamanca, Spain)
CASE PRESENTATION: INTEGRATING NOVEL THERAPY
IN THE TRANSPLANT PATIENT
J.L. Harousseau (Hôpital Hotel Dieu, Nantes, France)
SATELLITE SYMPOSIUM SUPPORTED BY MUNDIPHARMA
10.45 – 12.45 hours, Room: Y
PART 1
STATE-OF-THE-ART DIAGNOSIS, TREATMENT AND
PROPHYLAXIS IN AGGRESSIVE NHL AND ACUTE LEUKEMIA
Chair: C. Gisselbrecht (Paris, France)
INTRODUCTION
C. Gisselbrecht (Paris, France)
DIAGNOSIS OF CNS DISEASE IN AGGRESSIVE NHL
WITH FLOW CYTOMETRY
W. Wilson (Bethesda, USA)
|CNS DISEASE IN NHL: FROM TREATMENT TO
PROPHYLAXIS WITH LIPOSOMAL CYTARABINE
A. Pinto (Naples, Italy)
TREATMENT OF PRIMARY CNS LYMPHOMA WITH
HIGH-DOSE SYSTEMIC AND INTRATHECAL CHEMOTHERAPY WITHOUT RADIOTHERAPY
H. Pels (Bochum, Germany)
TREATMENT AND PROPHYLAXIS FOR CNS DISEASE IN
ALL: A EUROPEAN STUDY UPDATE
N. Gökbuget (Frankfurt, Germany)
PART 2
HIGHLY SELECTIVE INHIBITION OF PURINE NUCLEOSIDE PHOSPHORYLASE: A NEW
PRINCIPLE IN TREATING HAEMATOLOGICAL MALIGNANCIES
Chair: D. Hoelzer (Frankfurt, Germany)
INTRODUCTION
D. Hoelzer (Frankfurt, Germany)
MECHANISM OF ACTION OF FORODESINE AND
CLINICAL DATA IN THE TREATMENT OF T-CELL ALL
H. Kantarjian (Houston, USA)
RATIONALE AND CONCEPT IN INVESTIGATING
FORODESINE IN B-LINEAGE ALL
D. Hoelzer (Frankfurt, Germany)
SATELLITE SYMPOSIUM SUPPORTED BY GENZYME EUROPE BV
10.45 – 12.45 hours, Room A
THE SHERLOCK HOLMES APPROACH TO DIAGNOSIS AND TREATMENT: ANAEMIA AS A
CLUE IN RARE DISORDERS: AN INTERACTIVE LEARNING SESSION
10.45 – 10.55 hours
INTRODUCTION
P.C. Huijgens (VU University Medical Centre, Amsterdam,
The Netherlands)
10.55 – 11.10 hours
MYSTERY OF MASSIVE MACROPHAGE
M.D. Cappellini (University of Milan, Milan, Italy)
11.10 – 11.25 hours
THE SECRET WEAPON
C. Vallejo (University Hospital “Puerto de Hierro”, Madrid, Spain)
11.25 – 11.40 hours
THE NECKLACE OF PERLS
A. Mehta (Royal Free and UCL Medical School, London,
United Kingdom)
11.40 – 11.55 hours
MYSTERY IN THE MEDITERRANEAN
M.D. Cappellini (University of Milan, Milan, Italy)
11.55 – 12.10 hours
THE CASE OF THE PRIMIPARA MOTHER
C. Vallejo (University Hospital “Puerto de Hierro”, Madrid, Spain)
12.10 – 12.25 hours
THE CASE OF THE ENIGMATIC PARAPROTEIN
A. Mehta (Royal Free Hospital and UCL School of Medicine,
London, United Kingdom)
12.25 – 12.45 hours
QUESTIONS, SUMMARY AND CONCLUSIONS
P.C. Huijgens (VU University Medical Centre, Amsterdam,
The Netherlands)
SATELLITE SYMPOSIUM SUPPORTED BY ABBOTT MOLECULAR
10.45 – 12.45 hours, Room: B
THE ROLE OF MOLECULAR DIAGNOSTICS FOR PATIENT MANAGEMENT IN MULTIPLE
MYELOMA AND LEUKEMIA
Chair: R. Fonseca (Mayo Clinic, Scottsdale, USA)
DETECTION OF CYTOGENETIC ABNORMALITIES IN
MULTIPLE MYELOMA - WHAT IS THE IMPACT ON THE PATIENT?
R. Fonseca (Mayo Clinic, Scottsdale, USA)
SIGNIFICANCE OF PROGNOSTIC FACTORS IN CHRONIC
LYMPHOCYTIC LEUKEMIA AND IMPLICATIONS FOR PATIENT MANAGEMENT - THE ROLE
OF FISH
S. Stilgenbauer (University Clinic of Ulm, Ulm, Germany)
APPROACHES TO THE DIAGNOSIS AND MANAGEMENT OF
ACUTE LEUKEMIA AND CHRONIC MYELOGENOUS LEUKEMIA
C.J. Harrison (University of Southampton, Southampton, United Kingdom)
SATELLITE SYMPOSIUM SUPPORTED BY MERCK, SHARP AND DOHME
10.45 – 12.45 hours, Room: L
EVIDENCE-BASED OPTIONS FOR THE TREATMENT OF
FUNGAL INFECTIONS IN HIGH-RISK PATIENTS
Chair: P. Ribaud (Hôpital Saint-Louis, Paris, France)
10.45-10.50 hours
OPENING COMMENTS
P. Ribaud (Hôpital Saint-Louis, Paris, France)
10.50-11.15 hours
FUNGAL INFECTIONS ON THE RISE-HEMATOLOGIST TAKE
NOTE
L. Pagano (Istituto di ematologia UCSC-Roma, Rome, Italy)
11.15-11.50 hours
TREATMENT OPTIONS FOR SUSPECTED AND DOCUMENTED
FUNGAL INFECTIONS
O. Cornely (University of Cologne, Cologne, Germany)
11.50-12.15 hours
CASE STUDY REVIEW OF CASPOFUNGIN FOR THE
TREATMENT OF INVASIVE FUNGAL DISEASE
G. Jackson (University of Newcastle-Upon-Tyne, Newcastle,
United Kingdom)
12.15-12.40 hours
PANEL DISCUSSION
12.40-12.45 hours
CLOSING REMARKS
P. Ribaud (Hôpital Saint-Louis, Paris, France)
SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS ONCOLOGY
13.30 – 15.30 hours, Room: Auditorium
ADVANCING TYROSINE KINASE INHIBITION:
NEW STRATEGIES, NEW TOOLS
13.30 – 13.35 hours
INTRODUCTION
A. Hochhaus (University of Heidelberg, Mannheim, Germany)
13.35 – 13.55 hours
FIRST-LINE IMATINIB IN CML: A LONG-TERM
PERSPECTIVE
F. Guilhot (University Hospital CHU La Milétrie, Poitiers, France)
13.55 – 14.15 hours
USING HIGH-DOSE IMATINIB IN CML: WHY, WHEN,
HOW?
J.E. Cortes (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
14.15 – 14.35 hours
MOLECULAR MONITORING OF CML PATIENTS –
IS IT FEASIBLE IN CLINICAL PRACTICE?
G. Saglio (University of Turin, Obrassano, Italy)
14.35 – 14.55 hours
EMERGING THERAPEUTIC OPTIONS FOR IMATINIB
RESISTANT/REFRACTORY CML
F.J. Giles (The University of Texas M.D. Anderson Cancer Center,
Houston, USA)
14.55 – 15.15 hours
NEW FIELDS FOR TYROSINE KINASE INHIBITION
O.G. Ottmann (University of Frankfurt, Frankfurt, Germany)
15.15 – 15.25 hours
DISCUSSION, QUESTIONS AND ANSWERS
15.25 – 15.30 hours
SUMMARY AND CLOSE
A. Hochhaus (University of Heidelberg, Mannheim, Germany)
SATELLITE SYMPOSIUM SUPPORTED BY ORTHO BIOTECH /
JANSSEN - CILAG
13.30 – 15.30 hours, Room: Forum
PROTEASOME INHIBITION COMES OF AGE: MULTIPLE MYELOMA TREATMENTS FOR
PATIENTS OVER 60 YEARS
Chairs: H. Ludwig (Wilhelminenspital Vienna, Vienna, Austria)
J.F. San Miguel (University of Salamanca, Salamanca, Spain)
13.30 – 13.35 hours
WELCOME AND INTRODUCTION
13.35 – 13.50 hours
LATEST DEVELOPMENTS FOR PATIENTS AT FIRST
RELAPSE AND WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
M. Kropff (University Clinic of Münster, Münster, Germany)
13.50 – 14.05 hours
BROAD UTILITY OF BORTEZOMIB IN PATIENTS WITH
HIGH-RISK DISEASE, COMORBIDITIES OR SYMPTOMATIC DISEASE
M.A. Dimopoulos (The University of Athens School of Medicine, Athens,
Greece)
14.05 – 14.20 hours
MANAGEMENT OF SIDE EFFECTS OF NEW AGENTS
IN MULTIPLE MYELOMA
M. Delforge (University of Leuven, Leuven, Belgium)
14.20 – 14.35 hours
SUPPORTIVE CARE IN THE ELDERLY MULTIPLE MYELOMA
PATIENT
H. Ludwig (Wilhelminenspital Vienna, Vienna, Austria)
14.35 – 14.50 hours
RECENT DEVELOPMENTS FOR ELDERLY PATIENTS WITH
NEWLY DIAGNOSED MULTIPLE MYELOMA
J.F. San Miguel (University of Salamanca, Salamanca, Spain)
14.50 – 15.30 hours
PANEL DISCUSSION: WHERE DOES PROTEASOME
INHIBITION FIT IN THE MULTIPLE MYELOMA TREATMENT SEQUENCE FOR PATIENTS
OVER 60 YEARS?
SATELLITE SYMPOSIUM SUPPORTED BY ROCHE
13.30 – 15.30 hours, Room: X
PROVIDING ENERGY FOR LIFE – OPTIMISING ANAEMIA MANAGEMENT
13.30–13.40 hours
INTRODUCTION FROM THE CHAIR
G. Gaidano (University of Eastern Piedmont, Novara, Italy)
13.40–14.00 hours
ANAEMIA IN LYMPHOMA PATIENTS – WHAT ARE THE
CONSEQUENCES?
P. Soubeyran (Institut Bergonié, Bordeaux, France)
14.00–14.30 hours
EPOETIN AND SAFETY: MYTH VERSUS REALITY
W. Jelkmann (University of Luebeck, Luebeck, Germany)
B. Coiffier (Centre Hospitalier Lyon-Sud, Lyon, France)
14.30–14.50 hours
THE VALUE OF QUALITY OF LIFE – IMPROVING
OUTCOMES FOR YOUR PATIENTS
G. Gaidano (University of Eastern Piedmont, Novara, Italy)
14.50–15.10 hours
EMERGING INSIGHTS IN ANAEMIA MANAGEMENT
M.R. Nowrousian (University Hospital of Essen, Essen, Germany)
15.10–15.25 hours
QUESTIONS AND ANSWERS
All faculty members
15.25–15.30 hours
CONCLUSIONS FROM THE CHAIR
G. Gaidano (University of Eastern Piedmont, Novara, Italy)
Light refreshments will be provided
SATELLITE SYMPOSIUM SUPPORTED BY CELGENE,
BRISTOL-MYERS-SQUIBB ONCOLOGY AND SCHERING AG
13.30 – 15.30 hours, Room: Y
HEMATOLOGIC MALIGNANCIES: A RAPIDLY EVOLVING SPECTRUM OF THERAPEUTIC
OPTIONS
13.30 – 13.35 hours
WELCOME AND INTRODUCTION
H. Kantarjian (University of Texas, MD Anderson Cancer Center,
Houston, USA)
13.35 – 13.55 hours
MULTIPLE MYELOMA: A NEW THERAPEUTIC PARADIGM
A. Palumbo (University of Torino, Torino, Italy)
13.55 – 14.15 hours
NON-HODGKIN’S LYMPHOMA: WHAT’S NEW IN
RADIO- AND CHEMO-IMMUNOTHERAPY?
T. Illidge (Christie Hospital, University of Manchester, Manchester,
United Kingdom)
14.15 – 14.35 hours
CML AND PHILADELPHIA CHROMOSOME POSITIVE ALL:
OPTIMAL THERAPY FOR IMATINIB-RESISTANT PATIENTS
F. Cervantes (Hospital Clinic of Barcelona, Barcelona, Spain)
14.35 – 14.55 hours
CLL: DOES OPTIMIZING QUALITY OF THERAPEUTIC
RESPONSE IMPROVE OUTCOMES?
A. Osterborg (Karolinska Hospital, Stockholm, Sweden)
14.55 – 15.15 hours
MYELODYSPLATIC SYNDROMES: IMPORTANT STEPS
FORWARD
H. Kantarjian (University of Texas, MD Anderson Cancer Center,
Houston, USA)
15.15 – 15.30 hours
AUDIENCE QUESTIONS AND CONCLUDING REMARKS
SATELLITE SYMPOSIUM SUPPORTED BY PHARMION CORPORATION LTD.
13.30 – 15.30 hours, Room: A
DIAGNOSTIC AND THERAPEUTIC CHALLENGES IN MDS: A STATE-OF-THE-ART
ASSESSMENT
Chair: T. de Witte (Radboud University Medical Centre, Nijmegen,
The Netherlands)
13.00 – 13.30 hours
LUNCH BOX
13.30 – 15.30 hours
IPSS: WHAT DOES IT TELL US ABOUT PATIENT
SURVIVAL?
U. Germing (Düsseldorf University Hospital, Düsseldorf, Germany)
MDS WITH CYTOGENETIC ABNORMALITIES:
THERAPEUTIC DECISION-MAKING
G.J. Mufti (King’s College Hospital, London, United Kingdom)
DISRUPTING CHROMATIN TOPOLOGY:
MODELS FOR FUTURE CLINICAL TRIALS
G. Garcia-Manero (University of Texas, MD Anderson Cancer
Center, Houston, USA)
IMPROVING TREATMENT OUTCOMES IN MDS
V. Santini (University of Florence, Florence, Italy)
SATELLITE SYMPOSIUM
16.15 – 18.15 hours, Room: Auditorium
IMMUNOMODULATORY DRUGS – THE FOUNDATION FOR
TREATING HAEMATOLOGICAL MALIGNANCIES
Chairman: M. Dimopoulos (University of Athens School of Medicine,
Athens, Greece)
16.15 – 16.25 hours
WELCOME AND INTRODUCTION
M. Dimopoulos (University of Athens School of Medicine,
Athens, Greece)
16.25 – 16.45 hours
IMPROVING TREATMENT OUTCOMES BY UNDERSTANDING
CYTOGENETICS IN MYELODYSPLASTIC SYNDROMES
A. Giagounidis (St. Johannes Hospital, Duisburg, Germany)
16.45 – 17.05 hours
TRANSFUSION INDEPENDENCE AND CYTOGENETIC
RESPONSE IN MYELODYSPLASTIC SYNDROMES – WHAT THIS MEANS FOR THE PATIENT
A. List (H. Lee Moffitt Cancer Center, Tampa, USA)
17.05 – 17.25 hours
PROLONGING TIME TO PROGRESSION AND SURVIVAL IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA
P. Sonneveld (Erasmus Medical Center Rotterdam, Rotterdam,
The Netherlands)
17.25 – 17.45 hours
A NEW TREATMENT PARADIGM FOR CHRONIC
LYMPHOCYTIC LEUKAEMIA
A. Chanan-Khan (Roswell Park Cancer Institute, Buffalo, USA)
17.45 – 18.15 hours
PANEL DISCUSSION – A CHALLENGING DEBATE WITH
THE EXPERTS ON CONTROVERSIAL ISSUES IN THE
TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
Moderator: M. Dimopoulos (University of Athens School of
Medicine,
Athens, Greece)
This activity is jointly sponsored by the Elsevier Office of CME and
Excerpta Medica.The joint sponsors gratefully acknowledge the support of
an educational grant from Celgene. This activity has been approved for 2
AMA PRA Category 1 Credits™
SATELLITE SYMPOSIUM SUPPORTED BY ROCHE
16.15 – 18.15 hours, Forum
NHL – BUILDING ON THE EVIDENCE, REBUILDING LIVES
16.15 – 16.25 hours
WELCOME AND INTRODUCTION
A. Hagenbeek (University of Amsterdam, Amsterdam,
The Netherlands)
16.25 – 16.45 hours
IMPROVING OUTCOMES IN AGGRESSIVE NHL –
PRESENT AND FUTURE PERSPECTIVES
M. Pfreundschuh (Saarland University Medical School,
Homburg, Germany)
16.45 – 17.05 hours
CONFIRMING A SURVIVAL BENEFIT IN INDOLENT NHL –
THE EVIDENCE IS HERE: COCHRANE META-ANALYSIS
A. Engert (University Hospital of Cologne, Cologne, Germany)
17.05 – 17.30 hours
FIRST STEPS IN DEFINING A NEW STANDARD OF CARE
IN INDOLENT DISEASE: RESULTS FROM THE EORTC 20981 INTERGROUP STUDY
R. Klasa (British Columbia Cancer Research Center, Vancouver, Canada)
17.30 – 18.10 hours
RITUXIMAB MAINTENANCE THERAPY PANEL DISCUSSION:
IMPLICATIONS FOR CLINICAL PRACTICE FROM THE EORTC 20981 STUDY
M.H.J. van Oers (University of Amsterdam, Amsterdam, The Netherlands)
E. Kimby (Karolinska Institute, Stockholm, Sweden)
R. Klasa (British Columbia Cancer Research Center, Vancouver, Canada)
M. Wolf (Peter MacCallum Cancer Centre, Melbourne, Australia)
18.10 – 18.15 hours
SUMMARY AND CLOSING REMARKS
A. Hagenbeek (University of Amsterdam, Amsterdam,
The Netherlands)
Light refreshments will be provided
SATELLITE SYMPOSIUM SUPPORTED BY BRISTOL MYERS
SQUIBB ONCOLOGY
16.15 – 18.15 hours, Room: Y
NOVEL STRATEGIES IN THE MANAGEMENT OF IMATINIB -RESISTANT CHRONIC
MYELOGENOUS LEUKEMIA
Chairs: M. Baccarani (S. Orsola - Malpighi Hospital, Bologna, Italy)
M. Talpaz (University of Michigan Health Systems, Ann Arbor, USA)
16:15 – 16:20
WELCOME AND INTRODUCTION
M. Baccarani (S. Orsola - Malpighi Hospital, Bologna, Italy)
16:20 – 16:45
OPTIMAL MANAGEMENT OF CML: A CASE STUDY
J. Apperley (Imperial College School of Medicine, Hammersmith
Hospital, London, United Kingdom)
16:45 – 17:05
CELLULAR AND MOLECULAR MECHANISM OF
IMATINIB FAILURE IN CML
M. Talpaz (University of Michigan Health Systems, Ann Arbor, USA)
17:05 – 17:25
MOLECULAR MONITORING AS A BASIS FOR
CLINICAL DECISION MAKING IN CML
A. Hochhaus (University of Heidelberg, Mannheim, Germany)
17:25 – 17:45
IMATINIB-RESISTANT CML: CLINICAL IMPLICATIONS
M. Baccarani (S. Orsola - Malpighi Hospital, Bologna, Italy)
17:45 – 18:05
IMATINIB-RESISTANT CML: RESULTS OF CURRENT
CLINICAL TRIALS
F. Guilhot (University Hospital CHU La Milétrie, Poitiers, France)
18:05 – 18:15
AUDIENCE QUESTIONS AND CONCLUDING REMARKS
SATELLITE SYMPOSIUM SUPPORTED BY ORTHO BIOTECH /
JANSSEN - CILAG
16.15 – 18.15 hours, Room: A
NEW DIRECTIONS IN THE TREATMENT OF NON-HODGKIN’S LYMPHOMA AND
MYELODYSPLASTIC SYNDROMES
PART 1: THE POTENTIAL FOR PROTEASOME INHIBITION IN THE TREATMENT OF
NON-HODGKIN’S LYMPHOMA
16.15 – 16.20 hours
WELCOME AND INTRODUCTIONS
M. Dicato (Luxembourg Medical Centre, Luxembourg)
C. Gisselbrecht (Hopital Saint Louis, Paris, France)
16.20 – 16.35 hours
RATIONALE FOR PROTEASOME INHIBITION IN NHL
P.L. Zinzani (University of Bologna, Bologna, Italy)
16.35 – 16.50 hours
CLINICAL UPDATE OF BORTEZOMIB IN MANTLE CELL
LYMPHOMA
J. Drach (Medical University of Vienna, Vienna, Austria)
16.50 – 17.05 hours
INTEGRATING PROTEASOME INHIBITION INTO LYMPHOMA
TREATMENT
B. Coiffier (Hospices Civils de Lyon, Lyon, France)
17.05 – 17.15 hours
PANEL DISCUSSION: THE POTENTIAL FOR PROTEASOME
INHIBITION IN LYMPHOMA TREATMENT
NEW DIRECTIONS IN THE TREATMENT OF NON-HODGKIN’S LYMPHOMA AND
MYELODYSPLASTIC SYNDROMES
PART 2: NEW FRONTIERS IN THE TREATMENT OF
MYELODYSPLASTIC SYNDROMES
17.15 – 17.20 hours
WELCOME AND INTRODUCTION
M. Dicato (Luxembourg Medical Center, Luxembourg)
D. Hoelzer (University of Frankfurt, Frankfurt, Germany)
17.20 – 17.35 hours
TREATING SYMPTOMS IN PATIENTS WITH LOW GRADE
MDS: UPDATE ON ERYTHROPOIETIN RECEPTOR AGONISTS
A. Cortelezzi (University of Milan, Milan, Italy)
17.35 – 17.50 hours
NOVEL TREATMENT OPTIONS FOR PATIENTS WITH MDS
P. Fenaux (Hôpital Avicenne, Bobigny, France)
17.50 – 18.05 hours
UPDATE OF TIPIFARNIB IN PATIENTS WITH HIGH
GRADE MDS AND AML
T. de Witte (Radboud University Medical Centre, Nijmegen,
The Netherlands)
18.05 – 18.15 hours
PANEL DISCUSSION: LATEST DEVELOPMENTS IN THE
TREATMENT OF MDS
SATELLITE SYMPOSIUM SUPPORTED BY GLAXOSMITHKLINE
16.15 – 18.15 hours, Room: B
PROGRESS IN UNDERSTANDING AND TREATING IMMUNE
THROMBOCYTOPENIC PURPURA (ITP)
Chair: A. Newland (The Royal London Hospital, London, United Kingdom)
ITP: WHAT WE KNOW IN 2006 – UPDATE ON
PATHOPHYSIOLOGY, PREVALENCE AND SPECIAL POPULATIONS
A. Newland (The Royal London Hospital, London, United
Kingdom)
REEVALUATING TRADITIONAL TREATMENT APPROACHES
TO ITP: IMPACT ON GUIDELINES?
F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)
THE FUTURE OF ITP: TARGETED THERAPIES
J. Bussel (Weill Medical College of Cornell University, New York, USA)
REDEFINING THE MANAGEMENT OF ITP
J. Kelton (McMaster University, Hamilton, Ontario, Canada)
